CA3 (CIL56)

Catalog No.S8661 Batch:S866102

Print

Technical Data

Formula

C23H27N3O5S2
Molecular Weight 489.61 CAS No. 300802-28-2
Solubility (25°C)* In vitro DMSO 98 mg/mL (200.15 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
0.5mg/ml Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description CA3 (CIL56) has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. CA3(CIL56) induces ferroptosis and iron-dependent reactive oxygen species (ROS).
Targets
YAP/TEAD interaction [1]
In vitro

CA3 strongly inhibits esophageal adenocarcinoma cell growth in vitro. CA3 can effectively suppress tumor cell proliferation, induce apoptosis, reduce tumor sphere formation, and the population of ALDH1+ cells. CA3 specially inhibits Tead/YAP1 transcriptional activity but shows no inhibitory activity on other transcriptional factors-Super-TOP/Wnt, CBF1/Notch, and AP-1 after cotransfection of their respective individual promoter luciferases in 293T cells. CA3 preferentially inhibits CSC properties enriched in radiation-resistant esophageal adenocarcinoma cells[1].
In vivo

CA3 exerts strong antitumor activity in xenograft model with no apparent toxicity[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    SKGT-4 and JHESO cells

  • Concentrations

    0.5 and 1 μmol/L

  • Incubation Time

    48 hours

  • Method

    SKGT-4 and JHESO cells are seeded onto 6-well plates (1 × 105/well) in DMEM and cultured for 24 hours to allow for cell attachment. The cells are then treated with 0.1% DMSO (control) or CA3 at different doses as indicated for 48 hours. Next, the cells are harvested, fixed with methanol, washed, treated with RNase A, and stained for DNA with propidium iodide, and their DNA histograms and cell-cycle phase distributions are analyzed using flow cytometry.
Animal Study:

[1]
  • Animal Models

    A JHESO xenograft model of esophageal adenocarcinoma

  • Dosages

    1 mg/kg/mouse

  • Administration

    i.p.

Selleck's CA3 (CIL56) has been cited by 36 publications

Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity [ Cell Rep, 2024, 43(4):114003] PubMed: 38527062
The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells [ BMC Cancer, 2024, 24(1):587] PubMed: 38741073
YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape [ FEBS Open Bio, 2024, 10.1002/2211-5463.13901] PubMed: 39300603
EDA Fibronectin Microarchitecture and YAP Translocation During Wound Closure [ bioRxiv, 2024, 2024.09.23.614581] PubMed: 39386582
Microglia replacement by ER-Hoxb8 conditionally immortalized macrophages provides insight into Aicardi-Goutières Syndrome neuropathology [ bioRxiv, 2024, 2024.09.18.613629] PubMed: 39345609
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma [ Nat Commun, 2023, 14(1):6699] PubMed: 37872167
Musculoskeletal defects associated with myosin heavy chain-embryonic loss of function are mediated by the YAP signaling pathway [ EMBO Mol Med, 2023, e17187.] PubMed: 37492882
Extracellular Vesicles Derived circSH3PXD2A Inhibits Chemoresistance of Small Cell Lung Cancer by miR-375-3p/YAP1 [ Int J Nanomedicine, 2023, 18:2989-3006] PubMed: 37304971
Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms [ Cancers (Basel), 2023, 15(20)4960] PubMed: 37894327
Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms [ Cancers (Basel), 2023, 10.3390/cancers15204960] PubMed: 37894327

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.